Literature DB >> 12521651

Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial.

Marni Kwiecien1, Alison Edelman, Mark D Nichols, Jeffrey T Jensen.   

Abstract

The purpose of this study is to compare bleeding patterns and acceptability of a contraceptive regimen of combined 20 microg ethinyl estradiol/100 microg levonorgestrel taken with and without a hormone-free interval. Thirty-two women desiring oral contraception were randomized to six 28-day cycles (standard group) or 168 days without a pill-free interval (continuous group). Participants kept a daily bleeding calendar documenting bleeding events (none, spotting or required sanitary protection) and side effects (headache, nausea, breast tenderness, depression, premenstrual syndrome and bloating). Primary outcome was number of bleeding days. Secondary outcomes included bleeding days requiring sanitary protection, amenorrhea, patient acceptability of bleeding patterns, method satisfaction and affective side effects. There were no differences in the baseline characteristics of the two groups. Although total bleeding days were fewer in the continuous group (mean = 25.9 vs. 34.9 days), this result did not reach statistical significance. However, women in the continuous group reported significantly fewer bleeding days that required protection (18.4 vs. 33.8 days, p < 0.01), and were more likely to have amenorrhea. Although both groups reported a high level of satisfaction with bleeding patterns and side effect profiles, women in the continuous group reported significantly fewer days of bloating (0.7 vs. 11.1 days, p = 0.04), and menstrual pain (1.9 vs. 13.3 days, p < 0.01). Continuous use of 20 microg ethinyl estradiol/100 microg levonorgestrel is associated with less bleeding requiring protection, and more amenorrhea than standard administration. Taken with or without a hormone-free interval, this oral contraceptive formulation is highly acceptable with regard to bleeding patterns and side effect profile. The continuous group had fewer light and moderate bleeding days, less bloating and menstrual pain. For patients who are seeking these results, this method may be more desirable.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12521651     DOI: 10.1016/s0010-7824(02)00445-6

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  19 in total

Review 1.  Oral contraceptive pill for primary dysmenorrhoea.

Authors:  Chooi L Wong; Cindy Farquhar; Helen Roberts; Michelle Proctor
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

2.  Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial.

Authors:  Romana Dmitrovic; Allen R Kunselman; Richard S Legro
Journal:  Obstet Gynecol       Date:  2012-06       Impact factor: 7.661

Review 3.  Von Willebrand Disease: Current Status of Diagnosis and Management.

Authors:  Angela C Weyand; Veronica H Flood
Journal:  Hematol Oncol Clin North Am       Date:  2021-08-13       Impact factor: 3.722

Review 4.  Long-cycle treatment with oral contraceptives.

Authors:  Inka Wiegratz; Herbert Kuhl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Ovarian follicular development during the use of oral contraception: a review.

Authors:  Angela R Baerwald; Roger A Pierson
Journal:  J Obstet Gynaecol Can       Date:  2004-01

Review 6.  Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception.

Authors:  Alison Edelman; Elizabeth Micks; Maria F Gallo; Jeffrey T Jensen; David A Grimes
Journal:  Cochrane Database Syst Rev       Date:  2014-07-29

7.  Effects of continuous versus cyclical oral contraception: a randomized controlled trial.

Authors:  Richard S Legro; Jaimey G Pauli; Allen R Kunselman; Juliana W Meadows; James S Kesner; Richard J Zaino; Laurence M Demers; Carol L Gnatuk; William C Dodson
Journal:  J Clin Endocrinol Metab       Date:  2007-12-04       Impact factor: 5.958

8.  Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study.

Authors:  Christine Klipping; Ingrid Duijkers; Michel P Fortier; Joachim Marr; Dietmar Trummer; Jörg Elliesen
Journal:  J Fam Plann Reprod Health Care       Date:  2012-04

9.  New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control.

Authors:  Anita Nelson
Journal:  Int J Womens Health       Date:  2010-08-09

10.  Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives.

Authors:  Giuseppe Benagiano; Sabina Carrara; Valentina Filippi
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.